Bill Fleming, the chief financial officer of Oxitec Ltd, has joined the board of directors of OBN, the UK life sciences membership organisation. He has been at Oxitec, a unit of Intrexon Corp since 2010. Oxitec has developed a genetically modified mosquito to control the transmission of the Zika virus.
Prior to joining Oxitec, Mr Fleming held senior finance positions at Bayer Healthcare and before that, served as the European finance director at Visible Genetics Inc, a DNA sequencing company. He holds a law degree from the University of Cambridge and is a member of the Chartered Institute of Management Accountants.
OBN announced the appointment on 20 April 2017
Copyright 2017 Evernow Publishing Ltd